Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.
Charpentier C, Lambert-Niclot S, Larrouy L, Peytavin G, Valantin MA, Landman R, Katlama C, Yeni P, Felices M, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D. Charpentier C, et al. Among authors: felices m. J Acquir Immune Defic Syndr. 2011 May 1;57(1):e15-7. doi: 10.1097/QAI.0b013e3182139755. J Acquir Immune Defic Syndr. 2011. PMID: 21734472 No abstract available.
A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer.
Phung SK, Zorko NA, Soignier Y, Waller RL, Shackelford M, Walker JT, Nelson TD, Selleck C, Bendzick LE, Kotz LE, Kile QM, Bozicevich AJ, Miller SE, Khaw M, Shetty M, Hinderlie P, Ehrhardt M, Li Y, Luo X, Dehm SM, Antonarakis ES, Kennedy PR, Miller JS, Felices M. Phung SK, et al. Among authors: felices m. Cancer Immunol Res. 2024 Nov 15. doi: 10.1158/2326-6066.CIR-24-0273. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39545924
Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments.
Kennedy PR, Arvindam US, Phung SK, Ettestad B, Feng X, Li Y, Kile QM, Hinderlie P, Khaw M, Huang RS, Kaufman M, Puchalska P, Russell A, Butler J, Abbott L, McClure P, Luo X, Lu QT, Blazar BR, Crawford PA, Lim J, Miller JS, Felices M. Kennedy PR, et al. Among authors: felices m. Sci Adv. 2024 Nov;10(44):eadn1849. doi: 10.1126/sciadv.adn1849. Epub 2024 Oct 30. Sci Adv. 2024. PMID: 39475618 Free PMC article.
N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial.
Merino A, Brunstein CC, Shanley R, Rashid F, Wangen R, Bachanova V, Juckett M, Maakaron J, Felices M, Weisdorf D, Miller JS. Merino A, et al. Among authors: felices m. Transplant Cell Ther. 2024 Dec;30(12):1206.e1-1206.e12. doi: 10.1016/j.jtct.2024.09.023. Epub 2024 Oct 1. Transplant Cell Ther. 2024. PMID: 39362494 Clinical Trial.
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.
Matson AW, Hullsiek R, Dixon KJ, Wang S, Lindstedt AJ, Friess RR, Phung SK, Freedman TS, Felices M, Truckenbrod EN, Wu J, Miller JS, Walcheck B. Matson AW, et al. Among authors: felices m. J Immunother Cancer. 2024 Jul 24;12(7):e008959. doi: 10.1136/jitc-2024-008959. J Immunother Cancer. 2024. PMID: 39053944 Free PMC article.
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.
Matson AW, Hullsiek RH, Dixon KJ, Wang S, Lindstedt AJ, Friess RR, Phung SK, Freedman TS, Felices M, Truckenbrod EN, Wu J, Miller JS, Walcheck B. Matson AW, et al. Among authors: felices m. bioRxiv [Preprint]. 2024 May 14:2024.05.09.593347. doi: 10.1101/2024.05.09.593347. bioRxiv. 2024. Update in: J Immunother Cancer. 2024 Jul 24;12(7):e008959. doi: 10.1136/jitc-2024-008959 PMID: 38798522 Free PMC article. Updated. Preprint.
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES. Zorko NA, et al. Among authors: felices m. Prostate Cancer Prostatic Dis. 2024 Feb 28:10.1038/s41391-024-00797-0. doi: 10.1038/s41391-024-00797-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38418892
A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR, Vallera DA, Ettestad B, Hallstrom C, Kodal B, Todhunter DA, Bendzick L, Hinderlie P, Walker JT, Pulkrabek B, Pastan I, Kratzke RA, Fujioka N, Miller JS, Felices M. Kennedy PR, et al. Among authors: felices m. Front Immunol. 2023 Feb 22;14:1060905. doi: 10.3389/fimmu.2023.1060905. eCollection 2023. Front Immunol. 2023. PMID: 36911670 Free PMC article.
87 results